|
John Lowe, Ph.D.
Medicinal Chemistry
Dr. Lowe is a medicinal chemist with 30 years' experience in drug discovery and development at Pfizer, Inc. In 2002, he was appointed as senior research fellow, Pfizer’s top research position, which he held until his retirement in 2009. During his tenure, he discovered the first non-peptide substance P (NK1) receptor antagonist and the novel antipsychotic drug, ziprasidone. He is named as inventor or co-inventor on more than 60 patents. For his discovery of ziprasidone, Dr. Lowe was awarded the 2005 Northeast Regional Industrial Innovation Award and the 2007 ACS Heroes of Chemistry Award. He is also the recipient of the 2011 ACS Award in Industrial Chemistry.
|
|
Jeff Wilson, Ph.D.
CMC/Development Chemistry
Dr. Wilson has substantial expertise in CMC/development chemistry. He served as president of pharmaceutical development and manufacturing at Aptuit and VP of pharmaceutical operations at Vertex Pharmaceuticals. Early in his career he worked for Burroughs Wellcome as a product development chemist.
|
|
Andrea True Kelly, Ph.D.
Clinical Development
Dr. True Kelly served a pivotal role in creating and managing several clinical programs at Trimeris for both Fuzeon® (enfuvirtide) and the IND filing and first-in-man trial of its next-generation fusion inhibitor, TRI-1144. Her degree is in pharmacology.
|
|
John Dillberger, DMV, Ph.D.
Toxicology
Dr. Dillberger is a toxicologist who has worked for GlaxoSmithKline, Triangle Pharmaceuticals, and Argolyn Biosciences. He is currently a consultant and has been involved in numerous evaluations of novel chemical entities and regulatory submissions to the FDA.
|
|
Bill Wargin, Ph.D.
Clinical Pharmacology
Dr. Wargin is a consultant in the area of clinical pharmacology and was formerly employed by Burroughs Wellcome. He has written many sections for the registration of new chemical entities and has worked across numerous therapeutic areas.
|
|
Anne McKay, B.S.
Regulatory
Ms. McKay has more than 30 years of drug development experience in the area of regulatory affairs, including successful applications of over 100 NDAs and INDs across many therapeutic categories. She began her career at Burroughs Wellcome and has subsequently served as executive vice president of regulatory affairs and quality assurance at Triangle Pharmaceuticals and as vice president of regulatory affairs for Biolex Therapeutics.
|